Summary Using a Brown Norway rat leukaemia model (BNML), which is a realistic model of human myelocytic leukaemia, we compared the antileukaemic activity, influence on cell cycle kinetics and effect on normal haematopoiesis of 5 aza-2-deoxycytidine (aza-dC) and arabinofuranosyl-cytosine (ara-C). The antileukaemic activity was evaluated by means of a survival study. For aza-dC a dose-response relationship was demonstrated for doses up to 50mgkg-1 (3 times q 12h); a higher dose resulted in only a slight increase in median survival time (MST). For ara-C a weak dose-response relationship was observed. At the maximum dose of aza-dC and ara-C tested, aza-dC induced a 10-day longer survival time than ara-C, which means 2 logs more of leukaemic cell kill for aza-dC.
Arabinofuranosyl-cytosine (ara-C) is highly effective against acute leukaemias. However, in view of the high incidence of relapse, a considerable proportion of the leukaemic cells apparently resists treatment with ara-C.
In a search for other antileukaemic agents, we investigated a deoxycytidine analogue: 5 aza-2-deoxycytidine (aza-dC). Aza-dC has shown antineoplastic activity against some murine and human leukaemias (Momparler & Gonzales, 1978; Vesely & Czhak, 1977; Momparler et al., 1985a) . In mice inoculated with L1210 leukaemia. aza-dC was found to be more effective than ara-C (Momparler et al., 1985b) . To acquire antileukaemic activity ara-C has to be phosphorylated into its nucleotide form, ara-CTP, by deoxycytidine kinase and this metabolite is responsible for the inhibition of DNA synthesis. Furthermore, it has been observed that very low amounts of ara-C, which is incorporated into DNA by replacing dC, correlate with the per cent cell kill (Major et al., 1985) . The exact mechanism behind this killing of cells is still under investigation. Aza-dC, which very likely follows the same intracellular metabolic pathway as ara-C, is also an S phase-specific agent (Chabot & Momparler, 1986) . While it is assumed that ara-C cytotoxicity is a direct result of interference with DNA synthesis, aza-dC induces hypomethylation of DNA; the latter has been associated with altered gene expression, induction of differentiation and probably cell death (Jones & Taylor, 1980; Cleusat & Christman, 1982) . In mice there is a good correlation between the inhibition of DNA methylation produced by aza-dC and its antileukaemic activity (Wilson et al., 1983) .
In the present study we compared the antileukaemic activity, the influence on cell cycle kinetics and the effect on normal haematopoietic stem cells of aza-dC and ara-C in a realistic animal model of acute myelocytic leukaemia: Brown Norway rat myelocytic leukaemia. This model resembles more characteristics with AML than the L1210, i.e. (Colly et al., 1984b .
Results
Effect of aza-dC and ara-C on survival of leukaemic rats Figure 1 shows the dose-response relationship, as indicated by the increase in median survival time (MST), for both drugs for BNML rats and non-treated leukaemic control animals. The increase in MST can be considered as a parameter of the antileukaemic effect. All animals died of progressive leukaemia, except 2 rats in the ara-C group, who died within 12h after the first ara-C injection. These animals are presumed to be cases of toxic death and are therefore excluded from the data in Figure 1 . For aza-dC, MST increased in a dose-dependent fashion for dosages up to 50mg kg-1; higher dosages did not produce a significant improvement in MST. The dose response relationship for low dose ara-C did not. become clear in this study; at dosages exceeding 200mgkg-1 a slight increase in MST was observed. The MST curve for the aza-dC group is higher than that found for the ara-C group. At the highest dosages tested the increase in MST for ara-C was + 14 days and for aza-dC +24 days (P<0.001 t-test). Figure 2 shows the effects of an i.v. injection of ara-C or aza-dC on DNA synthesis in leukaemic bone marrow cells. In vitro 3H-thymidine incorporation into bone marrow cells dropped sharply after an ara-C injection to -50% of the initial value, followed by a sudden increase to -3 x the initial value 16h after the injection and normalization at the end of the study. In contrast to these observations, injection of aza-dC caused no changes in DNA synthesis; the results were comparable to those found for the control group.
The effects of ara-C and aza-dC on the percentage cells in S phase are shown in Figure 3 . In this experiment the values for the percentage cells in S phase after ara-C are similar to those observed in previous studies (Colly et al., 1984a) and show the pattern of synchronization of leukaemic cells, which is reflected in the accumulation of 50% cells in S phase. As in the 3HTdR uptake study no changes in the percentage cells in S phase occurred during the first 24 h after the aza-dC injection.
Effect of ara-C and aza-dC on CFU-S Figure 4 shows the toxic effects of various dosages of ara-C and aza-dC on haematopoietic stem cells, as indicated by a decrease in the number of rat bone marrow colonies growing in the spleens of irradiated mice.
Even at the lowest dose of aza-dC (5mgkg-1) tested, the number of colonies dropped to -60% of the initial value, a 
(r)
II i, plateau that persisted with increasing dosages. A similar pattern has been described for ara-C, although the plateau stabilized at + 75% of the initial value (Colly & Van Bekkum, 1982) . This difference between aza-dC and ara-C, however, was not significant (P=0.05, Mann-Whitney). The duration of suppression of the number of haematopoietic stem cells (CFU-S) produced by an injection of aza-dC (5mgkg-1) is shown in Figure 5 . The plateau of 60% was still evident 12h after injection.
Discussion
In previous studies the effect of aza-dC on acute leukaemia in mice and in vitro was investigated. An important question about this deoxycytidine analogue is whether or not this agent has advantages over ara-C. Since experience with the Brown Norway rat leukaemia model indicated that ara-C is an effective drug with moderate toxic side effects, this animal model is very suitable for such a study; moreover it simulates in a more precise way the characteristics of human leukaemia (Colly et al., 1984b (Colly et al., , 1986 .
Ara-C, the most active antileukaemic drug against human leukaemia, has been shown to increase the survival time for leukaemic Brown Norway rats in a weak dose-related fashion. A 5-fold increase in the dosage of 200mg kg-1 resulted in only a slight prolongation of survival time in this model. Since 200mg kg-1 body weight for a rat equals 1 gm-2 for man, this observation might indicate that the use of higher dosages of ara-C does not contribute to its antileukaemic effectiveness in man. For dosages up to 50mgkg-1 aza-dC, survival time increases in a dose-related fashion; however, no further increase in MST was observed at higher dosages. The MST at this plateau level is however much longer than the MST found for rats treated with highdose ara-C. Since in this model a linear relationship exists between the number of cells transplanted and survival of the recipients (Colly et al., 1984b) , the difference in the MST induced by each agent can be translated into the leukaemic cell kill. The increase in survival of 8-10 days induced by aza-dC means that 3 i.v. injections of the latter agent kills two logs more cells than 3 injections of ara-C (Colly et al., 1984b) .
In addition to its antileukaemic effect, the unique effects of ara-C on cell cycle kinetics (such as the G1/S blockade and cell recruitment and synchronization) have been studied in the rat model (Colly et al., 1984a) . In this model manipulation of these phenomena led to optimal treatment programs. However, clinical application of this knowledge has been hampered by the heterogeneity among human leukaemias (Colly et al., submitted) . A comparison of the effects on the cell cycles of ara-C and aza-dC, as illustrated in Figures 3 and 4 , reveals that the differences are striking. No alterations in cell cycle progression could be observed in the first 24h after an injection of aza-dC. This is compatible with our observation in leukaemic cell lines, that growth inhibition and cytotoxic effects became evident 2 cell cycles after incubation with aza-dC. Ultimately aza-dC induces cytotoxicity, as has been proven with colony formation assays (Momparler & Goodman, 1977) . It has been postulated that ara-C inhibits its own cell toxic actions by the G1/S blockade: since the cells accumulate at the G1 /S boundary, they do not enter S phase and are thus protected against cytotoxicity. Delay of cell cycle progression at G1/S could not be demonstrated for aza-dC, which might explain the greater antileukaemic activity observed.
Extreme haematological toxicity can limit the effectiveness of a cytostatic drug. Stem cell toxicity in man cannot be studied easily, but in the rat model it can be assessed by means of the CFU-S assay. Our study of ara-C and aza-dC showed that, in contrast to the dose-related antileukaemic activity, the maximum number of haematopoietic stem cells is already killed at relatively low dosages. Although there is a small difference between the two drugs in this respect, it is not significant. The latter observation combined with more effective antitumour effect of aza-dC implicates that aza-dC is a more effective antileukaemic agent than ara-C.
The difference between stem cell toxicity and antileukaemic effect favours treatment with high dosages of these agents, because the dose which causes maximal leukaemic cell kill is not more toxic for stem cells. During the first 12h after low dose aza-dC treatment (5mgkg-1) no recovery of initial stem cell values is observed. Longer follow up studies are required to study recovery from the toxic effect of aza-dC on stem cells. In summary it can be concluded that because of its increased antileukaemic activity, while the haematologic toxicity is comparable to ara-C, aza-dC might be very interesting clinically. In addition scientifically the many differences in biochemical properties with respect to ara-C also make it a fascinating agent. 
